Clinical Trials Logo

Filter by:
NCT ID: NCT04395768 Recruiting - COVID19 Clinical Trials

International ALLIANCE Study of Therapies to Prevent Progression of COVID-19

Start date: September 9, 2020
Phase: Phase 2
Study type: Interventional

COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.

NCT ID: NCT04394546 Active, not recruiting - Stroke Clinical Trials

CHAMPION-AF Clinical Trial

CHAMPION-AF
Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.

NCT ID: NCT04394117 Completed - COVID-19 Clinical Trials

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

CLARITY
Start date: June 19, 2020
Phase: Phase 4
Study type: Interventional

The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial. CLARITY aims to examine the effectiveness of angiotensin II receptor blockers (ARBs) on improving the outcomes of people who tested positive for COVID-19 disease.

NCT ID: NCT04392830 Completed - Healthy Clinical Trials

A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers

Start date: May 11, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALZ002 DS.

NCT ID: NCT04392154 Active, not recruiting - Atopic Dermatitis Clinical Trials

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

ADjoin
Start date: June 15, 2020
Phase: Phase 3
Study type: Interventional

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

NCT ID: NCT04391959 Completed - Clinical trials for Meibomian Gland Dysfunction

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Start date: July 17, 2020
Phase: Phase 2
Study type: Interventional

AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)

NCT ID: NCT04391569 Active, not recruiting - Status Epilepticus Clinical Trials

Randomized Therapy In Status Epilepticus

RAISE
Start date: October 10, 2020
Phase: Phase 3
Study type: Interventional

This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).

NCT ID: NCT04390763 Terminated - Clinical trials for Metastatic Pancreatic Ductal Adenocarcinoma

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

daNIS-1
Start date: October 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in untreated mPDAC.

NCT ID: NCT04389827 Recruiting - Kidney Diseases Clinical Trials

Global Kidney Patient Trials Network

Start date: May 5, 2020
Phase:
Study type: Observational [Patient Registry]

This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease

NCT ID: NCT04389775 Completed - Obesity Clinical Trials

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants

XW003
Start date: March 29, 2020
Phase: Phase 1
Study type: Interventional

XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management. This is a first-in-human (FIH), single-centre, double blind, randomised, SAD and MAD study of XW003 conducted in healthy adult participants. The study is designed to evaluate the safety, tolerability, PK, and PD of XW003 in healthy adult participants.